BioSpace News Archive

Drug Development

OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD™ Platform at AACR 2022 Annual Meeting

OncoNano Medicine, Inc. today announced positive results from the company’s ON-BOARD™ pH-sensitive nanoparticle platform.

April 12, 2022
·
2 min read
Drug Development

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

IO Biotech (Nasdaq: IOBT), announced today that it has dosed the first patient, in metastatic non-small cell lung cancer (NSCLC), in its Phase 2 IOB-022 / KN-D38 trial (NCT05077709).

April 12, 2022
·
3 min read
Biotech Bay

Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that management plans to participate in seven upcoming investor conferences.

April 12, 2022
·
2 min read
Biotech Bay

Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform

Personalis, Inc. announced the issuance of a key US Patent related to its industry-leading minimal residual disease (MRD) and recurrence platform, NeXT Personal.

April 12, 2022
·
4 min read
BioMidwest

Gb Sciences to Begin Dosage Study for Its Novel Parkinson’s Disease Formulations at the University of Lethbridge

Gb Sciences, Inc., a leading plant-inspired biopharmaceutical research and development company, has selected the University of Lethbridge in Canada to complete a dose range study of Gb Sciences’ patent-protected formulations in a rodent model of Parkinson’s disease.

April 12, 2022
·
7 min read
Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Thomas Heineman, M.D., Ph.D., the Company’s Chief Medical Officer, will be participating in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference.

April 12, 2022
·
4 min read
Drug Development

ZielBio to Present New Data Demonstrating Preclinical Efficacy of ZB131 in Cholangiocarcinoma at AACR Annual Meeting 2022

ZielBio, Inc. will present new, preclinical data on the efficacy of its ZB131 drug in cholangiocarcinoma (CCA) models at the American Association for Cancer Research (AACR) Annual Meeting 2022.

April 12, 2022
·
3 min read
Business

Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa

Actinium Pharmaceuticals, Inc. and Immedica Pharma AB (“Immedica”) today announced entering a license and supply agreement for Iomab-B,

April 12, 2022
·
9 min read
Business

VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B

VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) and AffaMed Therapeutics (AffaMed) today announced they have completed regulatory preparations to initiate PALISADE Global, a Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of VistaGen’s PH94B.

April 12, 2022
·
12 min read
SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months

Prilenia Therapeutics B.V. today announced that it has raised an additional $10 million, bolstering the Series B financing round and bringing total capital raised to date to $144 million.

April 12, 2022
·
5 min read